GILEAD SCIENCES, INC. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 65.96 USD | +2.14% |
|
+1.82% | -18.58% |
| May. 09 | Declaration of Voting Results by Gilead Sciences | CI |
| May. 09 | Declaration of Voting Results by Gilead Sciences | CI |
Days
Hours
Minutes
Seconds
-40%
on all our subscriptions*
Last Days!
Take advantage of the offer
* See conditions on site
Financials (USD)
| Sales 2024 * | 27.6B | Sales 2025 * | 28B | Capitalization | 82.18B |
|---|---|---|---|---|---|
| Net income 2024 * | 403M | Net income 2025 * | 6.35B | EV / Sales 2024 * | 3.64 x |
| Net Debt 2024 * | 18.15B | Net Debt 2025 * | 12.68B | EV / Sales 2025 * | 3.39 x |
| P/E ratio 2024 * |
187
x | P/E ratio 2025 * |
12.6
x | Employees | 18,000 |
| Yield 2024 * |
4.69% | Yield 2025 * |
4.93% | Free-Float | 99.9% |
More Fundamentals
* Assessed data
More news
Latest transcript on Gilead Sciences, Inc.
More recommendations
More press releases
| 1 day | +2.14% | ||
| 1 week | +1.82% | ||
| Current month | +1.17% | ||
| 1 month | -3.17% | ||
| 3 months | -10.47% | ||
| 6 months | -13.12% | ||
| Current year | -18.58% |
1 week
64.34
66.20
1 month
64.3368.62
Current year
64.3387.87
1 year
64.3387.87
3 years
57.1789.74
5 years
56.5689.74
10 years
56.56123.37
| Managers | Title | Age | Since |
|---|---|---|---|
Daniel O'Day
CEO | Chief Executive Officer | 59 | 19-02-28 |
Andrew Dickinson
DFI | Director of Finance/CFO | 54 | 15-12-31 |
Flavius Martin
CTO | Chief Tech/Sci/R&D Officer | - | 21-04-11 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Anthony Welters
BRD | Director/Board Member | 69 | 20-10-16 |
| Director/Board Member | 71 | 17-12-31 | |
Ted Love
BRD | Director/Board Member | 65 | Jan. 31 |
| Name | Weight | AuM | 1st Jan change | Investor Rating |
|---|---|---|---|---|
| 13.99% | 0 M€ | +12.39% | - | |
| 8.10% | 0 M€ | 0.00% | - | |
| 8.06% | 0 M€ | 0.00% | - | |
| 5.23% | 2 M€ | -.--% |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-05-10 | 65.96 | +2.14% | 8,733,211 |
| 24-05-09 | 64.58 | -0.52% | 6,048,572 |
| 24-05-08 | 64.92 | -0.82% | 5,134,980 |
| 24-05-07 | 65.46 | -0.12% | 7,318,161 |
| 24-05-06 | 65.54 | +1.17% | 7,187,265 |
Delayed Quote Nasdaq, May 10, 2024 at 04:00 pm EDT
More quotes
Gilead Sciences, Inc. specializes in the development, manufacturing and marketing of therapeutic products. Net sales break down by source of income as follows:
- sale of drugs (98.9%): for the treatment of HIV (63% of net sales), COVID-19 (20.4%), hepatitis C virus (6.6%), hepatitis B virus (3.6%) and other (6.4%; primarily cytomegalovirus retinitis, and advanced Kaposi sarcoma resulting from HIV);
- other (1.1%): especially royalties and revenue from research and development services and from subcontracted production of therapeutic products.
Net sales are distributed geographically as follows: the United States (69.2%), Europe (16.4%) and other (14.4%).
Sector
Pharmaceuticals
Calendar
2024-05-14
- BofA Securities Health Care Conference
Related indices
Trading Rating
Investor Rating
ESG Refinitiv
B-
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
31
Last Close Price
65.96
USD
Average target price
82.93
USD
Spread / Average Target
+25.73%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| -18.58% | 82.18B | |
| +30.38% | 684B | |
| +26.51% | 568B | |
| -4.36% | 361B | |
| +19.30% | 329B | |
| +3.73% | 284B | |
| +16.70% | 240B | |
| +8.78% | 208B | |
| -7.93% | 200B | |
| +7.68% | 166B |
- Stock Market
- Equities
- GILD Stock
